Sowell Financial Services LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 21.2% during the first quarter, Holdings Channel reports. The fund owned 4,188 shares of the medical research company’s stock after buying an additional 733 shares during the period. Sowell Financial Services LLC’s holdings in Amgen were worth $647,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the company. Jackson Grant Investment Advisers Inc. boosted its stake in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the last quarter. First Command Financial Services Inc. boosted its stake in Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock valued at $254,000 after buying an additional 17 shares during the last quarter. Cribstone Capital Management LLC boosted its stake in Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock valued at $182,000 after buying an additional 25 shares during the last quarter. Cable Hill Partners LLC boosted its stake in Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock valued at $161,000 after buying an additional 26 shares during the last quarter. Finally, Howe & Rusling Inc. boosted its stake in Amgen by 1.1% in the first quarter. Howe & Rusling Inc. now owns 2,956 shares of the medical research company’s stock valued at $485,000 after buying an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 79.12% of the company’s stock.
Shares of Amgen Inc. (AMGN) traded down 0.01% on Friday, reaching $167.80. 704,825 shares of the company were exchanged. The stock has a market capitalization of $122.44 billion, a PE ratio of 15.28 and a beta of 1.35. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $184.21. The company has a 50-day moving average price of $174.19 and a 200 day moving average price of $167.96.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 EPS. On average, analysts forecast that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date of this dividend is Tuesday, August 15th. Amgen’s dividend payout ratio is presently 41.93%.
ILLEGAL ACTIVITY NOTICE: “Sowell Financial Services LLC Acquires 733 Shares of Amgen Inc. (AMGN)” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/18/sowell-financial-services-llc-acquires-733-shares-of-amgen-inc-amgn.html.
Several research firms recently issued reports on AMGN. Mizuho set a $195.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Saturday, May 6th. UBS AG restated a “neutral” rating and set a $174.00 price objective (down from $175.00) on shares of Amgen in a research report on Monday, May 22nd. BMO Capital Markets restated a “buy” rating and set a $198.00 price objective (down from $200.00) on shares of Amgen in a research report on Monday, May 22nd. Morgan Stanley raised their price objective on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 13th. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $186.64.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.20% of the stock is owned by corporate insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.